Journal
CELL REPORTS
Volume 28, Issue 9, Pages 2345-+Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2019.07.070
Keywords
-
Categories
Funding
- Netherlands Organization for Scientific Research [NWO-VIDI 916-76062]
- European Research Council [ERC CoG 682421]
- Dutch Cancer Society [RUG 2011-5093]
- Rene Vogels Foundation
- De Boer-Merema Foundation
- American Cancer Society [RSG-17-011-01]
- NIGMS/NIH [R01GM127559]
- Translational Cancer Biology Training Grant [T32-CA130807]
Ask authors/readers for more resources
Triple-negative breast cancers (TNBCs) display great diversity in cisplatin sensitivity that cannot be explained solely by cancer-associated DNA repair defects. Differential activation of the DNA damage response (DDR) to cisplatin has been proposed to underlie the observed differential sensitivity, but it has not been investigated systematically. Systems-level analysis-using quantitative time-resolved signaling data and phenotypic responses, in combination with mathematical modeling-identifies that the activation status of cell-cycle checkpoints determines cisplatin sensitivity in TNBC cell lines. Specifically, inactivation of the cell-cycle checkpoint regulator MK2 or G3BP2 sensitizes cisplatin-resistant TNBC cell lines to cisplatin. Dynamic signaling data of five cell cycle-related signals predicts cisplatin sensitivity of TNBC cell lines. We provide a time-resolved map of cisplatin-induced signaling that uncovers determinants of chemo-sensitivity, underscores the impact of cell-cycle checkpoints on cisplatin sensitivity, and offers starting points to optimize treatment efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available